NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Wednesday, October, 30th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.12. The biotechnology company had revenue of $271.70 million for the quarter, compared to analyst estimates of $228.17 million. Exelixis had a return on equity of 25.55% and a net margin of 64.05%. Exelixis's revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.44 earnings per share. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Exelixis.

11 Wall Street analysts have issued 12 month target prices for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they expect Exelixis' share price to reach $26.50 in the next year. This suggests a possible upside of 33.7% from the stock's current price. View Analyst Price Targets for Exelixis.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Media headlines about EXEL stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exelixis earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Exelixis.

Exelixis saw a increase in short interest in December. As of December 31st, there was short interest totalling 18,100,000 shares, an increase of 17.0% from the December 15th total of 15,470,000 shares. Based on an average daily trading volume, of 2,910,000 shares, the short-interest ratio is presently 6.2 days. Currently, 6.2% of the company's shares are sold short. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Incyte (INCY), Intel (INTC), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Cisco Systems (CSCO).

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (0.27%), Tealwood Asset Management Inc. (0.04%), Louisiana State Employees Retirement System (0.02%), Assenagon Asset Management S.A. (0.02%), State of Alaska Department of Revenue (0.02%) and Alpine Global Management LLC (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc., State of Alaska Department of Revenue and Sonora Investment Management LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Alpine Global Management LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, Huntington National Bank, Manchester Financial Inc. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $19.82.

Exelixis has a market capitalization of $6.02 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

The official website for Exelixis is http://www.exelixis.com/.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]